BriaCell is an immuno oncology focused biotechnology company developing a targeted and safe approach to the management of cancer, including the first off the shelf personalized approach to immunotherapy. The company is currently conducting a Phase IIa clinical trial for its lead product candidate, Bria IMT, in patients with advanced breast cancer. This trial is listed in ClinicalTrials.gov as NCT . The trial is being conducted along with the co development of BriaDX, the Company s companion diagnostic test. Additionally, there is an FDA approved roll over combination study of Bria IMT with pembrolizumab Keytruda manufactured by Merck amp Co., Inc. or ipilimumab Yervoy manufactured by Bristol Myers Squibb Company for patients with advanced breast cancer previously treated with Bria IMT. The roll over trial is listed in ClinicalTrials.gov as NCT . Additionally, BriaCell is developing Bria OTS, the first off the shelf personalized treatment for advanced stage Breast Cancer. Finally, BriaCell s small molecule program consists of novel, selective protein kinase C delta PKCo inhibitors. PKCo inhibitors have shown activity in a number of pre clinical models of RAS genes transformed cancers including breast, pancreatic, non small cell lung cancer, melanoma and neuroendocrine tumors such as carcinoid tumors . This technology also has applications for treating patients with fibrotic diseases
Quote | BriaCell Therapeutics (OTCMKTS:BCTXF)
Last: | $5.95 |
---|---|
Change Percent: | -1.32% |
Open: | $6.018 |
Close: | $5.95 |
High: | $6.018 |
Low: | $5.95 |
Volume: | 2,095 |
Last Trade Date Time: | 02/23/2021 04:53:47 pm |
News | BriaCell Therapeutics (OTCMKTS:BCTXF)
Clinical and pathological findings from clinical trial of the Bria-IMT™ regimen alone and in combination with immune checkpoint inhibitors in advanced breast cancer will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2021, April 10-15 and May...
BERKELEY, Calif. and VANCOUVER, British Columbia, Feb. 26, 2021 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (TSX-V:BCT) (NASDAQ: BCTX, BCTXW) (“BriaCell” or the “Company”) , a clinical-stage biotechnology company specializing in targeted immunotherapies f...
Message Board Posts | BriaCell Therapeutics (OTCMKTS:BCTXF)
Subject | By | Source | When |
---|---|---|---|
No posts yet. |
News, Short Squeeze, Breakout and More Instantly...
BriaCell Therapeutics Company Name:
BCTXF Stock Symbol:
OTCMKTS Market:
BriaCell Therapeutics Website:
Clinical and pathological findings from clinical trial of the Bria-IMT™ regimen alone and in combination with immune checkpoint inhibitors in advanced breast cancer will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2021, April 10-15 and May...
BERKELEY, Calif. and VANCOUVER, British Columbia, Feb. 26, 2021 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (TSX-V:BCT) (NASDAQ: BCTX, BCTXW) (“BriaCell” or the “Company”) , a clinical-stage biotechnology company specializing in targeted immunotherapies f...
BERKELEY, Calif. and VANCOUVER, British Columbia, Feb. 23, 2021 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (TSX-V:BCT) (NASDAQ: BCTX, BCTXW) (“BriaCell” or the “Company”) , a clinical-stage biotechnology company specializing in targeted immunotherapies f...